25 May 2013
Keywords: strong, ph, ii, data, novartis, menb, vacc
Article | 26 May 2008
Swiss drug major Novartis says that new mid-stage data on MenB, its investigational recombinant meningococcal group B vaccine, support its
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 May 2008
24 May 2013
© 2013 thepharmaletter.com